ImmuPharma (25I) Stock Price & Analysis
25I Stock Chart & Stats
- Day’s Range
- EUR 0.02 - EUR 0.03
- 52-Week Range
- EUR 0.02 - EUR 0.12
- Previous Close
- EUR 0.03
- Volume
- N/A
- Average Volume (3M)
- 2,576
- Market Cap
- EUR 24.30M
- Enterprise Value
- EUR 20.22M
- Total Cash (Recent Filing)
- EUR 695.84K
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- 6.97
- Next Earnings
- May 25, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Financial Leverage
Debt at or near zero reduces default and refinancing pressure, preserving financial flexibility while the company advances its pharmaceutical assets. Although the business remains loss-making, a lightly leveraged balance sheet avoids adding significant interest obligations or creditor constraints to future funding decisions.
Improved Equity Base
The move from negative to positive equity indicates a stronger reported capital base than in 2024, while total assets reached approximately £3.1m TTM. This provides a more stable foundation for continued development activity, even though the assets are not yet producing positive returns.
Specialized Partnering Model
A focused immunology pipeline combined with licensing and co-development routes can let ImmuPharma pursue specialized therapies without building a large integrated sales organization. If development milestones are achieved, partnerships could provide commercialization reach and preserve strategic flexibility over time.
Bears Say
No Meaningful Revenue Base
Effectively zero revenue means the company currently lacks a recurring operating income base to fund research, overhead, or future development internally. This leaves financial progress highly dependent on successful asset advancement and potential external transactions rather than established commercial demand.
Widening Losses
The sharp increase in net loss shows that the current cost structure is consuming substantially more capital without corresponding revenue generation. Persistent negative EBIT and EBITDA indicate that profitability is not yet supported by operations, increasing the funding burden as development work continues.
Sustained Cash Burn
Consistently negative operating and free cash flow demonstrates that ongoing activities require cash from outside the business. The deterioration in free cash flow versus 2025 raises the risk that additional financing will be needed before pharmaceutical assets can generate licensing, milestone, royalty, or other operating proceeds.
ImmuPharma News
25I FAQ
What was ImmuPharma’s price range in the past 12 months?
What is ImmuPharma’s market cap?
When is ImmuPharma’s upcoming earnings report date?
How were ImmuPharma’s earnings last quarter?
Is ImmuPharma overvalued?
Does ImmuPharma pay dividends?
What is ImmuPharma’s EPS estimate?
How many shares outstanding does ImmuPharma have?
What happened to ImmuPharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ImmuPharma?
What is the TipRanks Smart Score and how is it calculated?
Company Description
ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Timothy Paul McCarthy
- Employees
- 7
- Website
- www.immupharma.co.uk
- Address
- One Bartholomew Close, London, GL, EC1A 7BL, GB
ImmuPharma (25I) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |
